These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 28111882)
1. Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors. Kumar SR; Kim DY; Henry CJ; Bryan JN; Robinson KL; Eaton AM Vet Comp Oncol; 2017 Dec; 15(4):1527-1536. PubMed ID: 28111882 [TBL] [Abstract][Full Text] [Related]
2. Checkpoint molecule expression by B and T cell lymphomas in dogs. Hartley G; Elmslie R; Dow S; Guth A Vet Comp Oncol; 2018 Sep; 16(3):352-360. PubMed ID: 29380929 [TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death Ligand 1 Expression in Canine Cancer. Shosu K; Sakurai M; Inoue K; Nakagawa T; Sakai H; Morimoto M; Okuda M; Noguchi S; Mizuno T In Vivo; 2016; 30(3):195-204. PubMed ID: 27107075 [TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of the death-associated protein kinase CpG island in canine B-cell lymphoid tumors. Sato M; Mochizuki H; Goto-Koshino Y; Fujiwara-Igarashi A; Takahashi M; Fujino Y; Ohno K; Tsujimoto H Vet Immunol Immunopathol; 2014 Oct; 161(3-4):222-31. PubMed ID: 25193469 [TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239 [TBL] [Abstract][Full Text] [Related]
6. Immune regulation of canine tumour and macrophage PD-L1 expression. Hartley G; Faulhaber E; Caldwell A; Coy J; Kurihara J; Guth A; Regan D; Dow S Vet Comp Oncol; 2017 Jun; 15(2):534-549. PubMed ID: 26842912 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma. Tagawa M; Kurashima C; Takagi S; Maekawa N; Konnai S; Shimbo G; Matsumoto K; Inokuma H; Kawamoto K; Miyahara K PLoS One; 2018; 13(7):e0201222. PubMed ID: 30040869 [TBL] [Abstract][Full Text] [Related]
9. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575 [TBL] [Abstract][Full Text] [Related]
10. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629 [TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968 [TBL] [Abstract][Full Text] [Related]
12. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323 [TBL] [Abstract][Full Text] [Related]
13. Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma. Ambrosius LA; Dhawan D; Ramos-Vara JA; Ruple A; Knapp DW; Childress MO Am J Vet Res; 2018 Jun; 79(6):643-649. PubMed ID: 30085860 [TBL] [Abstract][Full Text] [Related]
14. Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. Maekawa N; Konnai S; Ikebuchi R; Okagawa T; Adachi M; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Murata S; Ohashi K PLoS One; 2014; 9(6):e98415. PubMed ID: 24915569 [TBL] [Abstract][Full Text] [Related]
15. PD-1 expression by canine T cells and functional effects of PD-1 blockade. Coy J; Caldwell A; Chow L; Guth A; Dow S Vet Comp Oncol; 2017 Dec; 15(4):1487-1502. PubMed ID: 28120417 [TBL] [Abstract][Full Text] [Related]
16. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. Gowrishankar K; Gunatilake D; Gallagher SJ; Tiffen J; Rizos H; Hersey P PLoS One; 2015; 10(4):e0123410. PubMed ID: 25844720 [TBL] [Abstract][Full Text] [Related]
17. Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry. Gelain ME; Mazzilli M; Riondato F; Marconato L; Comazzi S Vet Immunol Immunopathol; 2008 Feb; 121(3-4):179-88. PubMed ID: 17981339 [TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation. Liu L; Zheng Q; Lee J; Ma Z; Zhu Q; Wang Z J Cell Mol Med; 2015 Jun; 19(6):1223-33. PubMed ID: 25810125 [TBL] [Abstract][Full Text] [Related]